L-Dopa Responsiveness is Correlated to Fluorodeoxyglucose Metabolism and Dopamine Transporter Availability in Parkinson's Disease

被引：0
|
作者：
Su, D.
Hu, W.
Zhao, X.
Liu, Z.
Ma, H.
Zhou, J.
Feng, T.
机构：
来源：
MOVEMENT DISORDERS | 2018年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
1486
引用
收藏
页码：S697 / S698
页数：2
相关论文
共 50 条
  • [1] Duration of L-dopa and dopamine agonist monotherapy in Parkinson's disease
    Nissen, T.
    Newman, E. J.
    Grosset, K. A.
    Daghem, M.
    Pal, G.
    Stewart, M.
    Odin, P.
    Macphee, G. J.
    Grosset, D. G.
    MOVEMENT DISORDERS, 2011, 26 : S259 - S259
  • [2] Duration of L-dopa and dopamine agonist monotherapy in Parkinson's disease
    Nissen, T.
    Newman, E. J.
    Grosset, K. A.
    Daghem, M.
    Pal, G.
    Stewart, M.
    Odin, P.
    Macphee, G. J.
    Grosset, D. G.
    SCOTTISH MEDICAL JOURNAL, 2012, 57 (04) : 217 - 220
  • [3] L-Dopa Responsiveness Is Associated With Distinctive Connectivity Patterns in Advanced Parkinson's Disease
    Akram, Harith
    Wu, Chengyuan
    Hyam, Jonathan
    Foltynie, Thomas
    Limousin, Patricia
    De Vita, Enrico
    Yousry, Tarek
    Jahanshahi, Marjan
    Hariz, Marwan
    Behrens, Timothy
    Ashburner, John
    Zrinzo, Ludvic
    MOVEMENT DISORDERS, 2017, 32 (06) : 874 - 883
  • [4] L-dopa responsiveness in early Parkinson's disease is associated with the rate of motor progression
    Malek, Naveed
    Kanavou, Sofia
    Lawton, Michael A.
    Pitz, Vanessa
    Grosset, Katherine A.
    Bajaj, Nin
    Barker, Roger A.
    Ben-Shlomo, Yoav
    Burn, David J.
    Foltynie, Tom
    Hardy, John
    Williams, Nigel M.
    Wood, Nicholas
    Morris, Huw R.
    Grosset, Donald G.
    PARKINSONISM & RELATED DISORDERS, 2019, 65 : 55 - 61
  • [5] L-dopa response in Parkinson's disease - A study with L-dopa infusion test
    Saiki, H.
    Matsumoto, S.
    MOVEMENT DISORDERS, 2012, 27 : S50 - S50
  • [6] Dopamine and L-dopa disaggregate amyloid fibrils: implications for Parkinson's and Alzheimer's disease
    Li, J
    Zhu, M
    Manning-Bog, AB
    Di Monte, DA
    Fink, AL
    FASEB JOURNAL, 2004, 18 (06): : 962 - +
  • [7] Unpredictable Rotational Responses to L-dopa in the Rat Model of Parkinson's Disease: the Role of L-dopa Pharmacokinetics and Striatal Dopamine Depletion
    Kaariainen, Tiina M.
    Kaenmaki, Mikko
    Forsberg, Markus M.
    Oinas, Niko
    Tammimaki, Anne
    Mannisto, Pekka T.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2012, 110 (02) : 162 - 170
  • [8] Plasma homocysteine and L-DOPA metabolism in patients with Parkinson disease
    Blandini, F
    Fancellu, R
    Martignoni, E
    Mangiagalli, A
    Pacchetti, C
    Samuele, A
    Nappi, G
    CLINICAL CHEMISTRY, 2001, 47 (06) : 1102 - 1104
  • [9] Peculiarities of L-DOPA treatment of Parkinson’s disease
    R. M. Kostrzewa
    P. Nowak
    J. P. Kostrzewa
    R. A. Kostrzewa
    R. Brus
    Amino Acids, 2005, 28 : 157 - 164
  • [10] Monitoring of L-dopa concentrations in Parkinson's disease
    Furlanut, M
    Furlanut, M
    Benetello, P
    PHARMACOLOGICAL RESEARCH, 2001, 43 (05) : 423 - 427
12345